e-learning
resources
Berlin 2008
Sunday, 05.10.2008
Management, quality aspects and prognosis in thoracic oncology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Use of FDG-PET in the investigative pathway for lung cancer – real world experience in Southern England
M. Schuhmann, H. Rupani, K. Adenji, K. McKinlay, M. Roland (Portsmouth, Basingstoke, Southampton, United Kingdom)
Source:
Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology
Session:
Management, quality aspects and prognosis in thoracic oncology
Session type:
E-Communication Session
Number:
1410
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Schuhmann, H. Rupani, K. Adenji, K. McKinlay, M. Roland (Portsmouth, Basingstoke, Southampton, United Kingdom). Use of FDG-PET in the investigative pathway for lung cancer – real world experience in Southern England. Eur Respir J 2008; 32: Suppl. 52, 1410
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Towards personalized lung cancer CT screening in Europe
Source: Virtual Congress 2020 – Screening and imaging in lung cancer
Year: 2020
Initial experience in the use of PET-CT for the evaluation and follow-up of lung cancer at the Singapore General Hospital
Source: Eur Respir J 2004; 24: Suppl. 48, 300s
Year: 2004
The approach to the surgical management of cancer in four European countries
Source: Eur Respir J 2003; 22: 838-844
Year: 2003
An audit on the use of FDG-PET in the diagnosis and management of lung cancer in a district general hospital in the West Midlands, U.K.
Source: Annual Congress 2010 - Quality management for lung cancer patients
Year: 2010
Cytological types of lung cancer in a referral population in Western Greece during the past decade
Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer
Year: 2014
Rationalising the lung cancer diagnostic pathway with CT triage; a single centre UK experience.
Source: Virtual Congress 2020 – Management issues in thoracic oncology
Year: 2020
A regional study of bronchoscopic diagnostic yield rates for lung cancer involving centres of the Thames Valley Cancer Network (TVCN), UK
Source: Annual Congress 2010 - The role of endoscopy in the diagnosis of lung cancer
Year: 2010
Initial symptoms and diagnostic delays of lung cancer in southern Norway
Source: Eur Respir J 2006; 28: Suppl. 50, 127s
Year: 2006
The impact of specialist lung cancer clinics on government targets in patients referred with suspected lung cancer in the University Hospital of North Staffordshire, UK
Source: Eur Respir J 2007; 30: Suppl. 51, 666s
Year: 2007
Impact of PET scan on staging and management of lung cancer patients in Indian scenario
Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer
Year: 2013
Should resection rate increase when PET-CT use increases? An analysis of PET-CT use in large UK lung cancer network 2011 - 2013
Source: International Congress 2015 – Quality management in lung cancer
Year: 2015
Implementation of lung cancer screening in Europe: the way forward
Source: Virtual Congress 2020 – Thoracic oncology
Year: 2020
Is there equitable access to PET-CT for lung cancer patients across a large UK cancer network; a retrospective study of 4597 patients
Source: International Congress 2015 – Quality management in lung cancer
Year: 2015
Management of lung cancer screening and incidental findings as well as their integration in existing lung cancer care
Source: International Congress 2019 – PG1 Lung cancer: the key multidisciplinary approach
Year: 2019
The feasibility of a lung cancer screening program in rural Ireland
Source: Eur Respir J 2006; 28: Suppl. 50, 80s
Year: 2006
Impact of PET scanning on lung cancer management in a U.K. centre
Source: Eur Respir J 2006; 28: Suppl. 50, 83s
Year: 2006
ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe
Source: International Congress 2018 – State of the art session: Thoracic oncology
Year: 2018
ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe
Source: Guideline 2018
Year: 2018
ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe
Source: Eur Respir J, 52 (6) 1800610; 10.1183/13993003.00610-2018
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept